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A novel method for predicting maximum recommended therapeutic dose (MRTD) is presented using quantitative structure
property relationships (QSPRs) and artiﬁcial neural networks (ANNs). MRTD data of 31 structurally diverse Antiretroviral drugs
(ARVs) were collected from FDA MRTD Database or package inserts. Molecular property descriptors of each compound, that is,
molecular mass, aqueous solubility, lipophilicity, biotransformation half life, oxidation half life, and biodegradation probability
were calculated from their SMILES codes. A training set (n = 23) was used to construct multiple linear regression and back
propagation neural network models. The models were validated using an external test set (n = 8) which demonstrated that MRTD
values may be predicted with reasonable accuracy. Model predictability was described by root mean squared errors (RMSEs),
Kendall’s correlation coeﬃcients (tau), P-values, and Bland Altman plots for method comparisons. MRTD was predicted by a
6-3-1 neural network model (RMSE = 13.67, tau = 0.643, P = 0.035) more accurately than by the multiple linear regression
(RMSE = 27.27, tau = 0.714, P = 0.019) model. Both models illustrated a moderate correlation between aqueous solubility of
antiretroviral drugs and maximum therapeutic dose. MRTD prediction may assist in the design of safer, more eﬀective treatments
for HIV infection.
1.Introduction
Acquired immunodeﬁciency syndrome (AIDS) is a degen-
erative disease of the immune and central nervous sys-
tems caused by the human immunodeﬁciency virus (HIV).
There are an estimated 33.2 million people living with
HIV/AIDS globally [1–3]. Of this number, 22.5 million
are in Sub-Saharan Africa, which represents 67.8% of
the global number [3]. Antiretroviral drugs (ARVs) may
be classiﬁed as nucleoside reverse transcriptase inhibitors
(NRTIs),nucleotidereversetranscriptaseinhibitors(NtRTI),
non-nucleoside reverse transcriptase inhibitors (NNRTIs),
protease inhibitors (PI), and more recently as fusion or inte-
grase inhibitors [4, 5] .S i n c em o s tA R V sh a v el o wa q u e o u s
solubility and poor bioavailability, several alternative drug
delivery strategies have been proposed to optimize systemic
concentrations [6, 7]. The important biopharmaceutical
properties that need to be considered for eﬀective ARV
delivery systems might include solubility, pKa, lipophilicity,
permeability, stability in biological ﬂuids, gastrointestinal
metabolism, and where possible viral reservoir targeting [6,
8,9].Toovercomesuboptimalbiopharmaceuticalproperties,
ARVs are often prescribed at high daily doses which increase
the occurrence of adverse side eﬀects and toxicities [10, 11].
Combination therapy, comprising at least three anti-HIV
drugs, has become a standard treatment of AIDS [12], but
here again the potential for adverse side eﬀects and drug-
related noncompliance increases. To address these issues,
computational methods have been used to predict dose-
limiting toxicities of a few antiretroviral drugs [13, 14]o rt o
optimize ARV formulations [15, 16]. The ability to predict
maximum therapeutic dose directly from molecular struc-
ture is both clinically and scientiﬁcally attractive in terms
of treatment management and reducing drug development
costs [17]. Unfortunately, such models for drugs used in
the treatment of AIDS do not yet exist. Accurate prediction2 Computational and Mathematical Methods in Medicine
of the MRTD for antiretroviral type compounds would be
particularly useful in formulation studies so that clinically
relevantextrapolationsondrugdissolution andpermeability
can be made earlier in the drug development process [17–
20]. Several recent studies have been conducted to deﬁne
a relationship between the dose and physicochemical prop-
erties of the drug [20, 21], or to investigate the underlying
mechanisms of drug toxicity and bioaccumulation [20, 22].
Still, the prediction of optimal dose continues to challenge
pharmaceutical scientists because of its complexity and
variability between diﬀerent organisms. Artiﬁcial neural net-
w o r k s( A N N s )h a v ee m e r g e da sap o w e r f u lt o o ls u i t a b l ef o r
processing complex relationships between molecular stimuli
and biological system responses [23]. Examples include
prediction of warfarin maintenance dose [24], gentamicin
steady-state plasma concentrations [25], skin permeability
[26], and prediction of HIV drug resistance [27]; supporting
data for these and other studies suggest the utility of neural
network modeling for predicting maximum therapeutic
doses.
We believed that since the MRTD estimates are derived
from human data, they would provide a more relevant,
accurate, and speciﬁc estimate for toxic dose levels compared
to risk assessment models based on animal data alone. In this
article, we predict the MRTD of antiretroviral drugs from
their molecular structures using relevant molecular property
descriptors and neural network software as a data mining
tool. Predictive performance of the models were evaluated
and statistically compared with the results obtained clinically
or reported in the literature. The application of predictive
models in the design of safe, eﬀective antiretroviral drug
delivery systems is discussed.
2.MaterialsandMethods
2.1. Chemoinformatic Software and Modeling Tools. The
physicochemical descriptors, molecular weight (MW), aque-
ous solubility (ASol), and lipophilicity (AlogP) were deter-
minedusingALOGPS2.1.VirtualComputationalChemistry
Laboratory, (http://www.vcclab.org/)[ 28, 29]. Bioaccumu-
lation descriptors, log biotransformation half life (log-
BioHL), oxidation half life (OxidHL), and biodegrada-
tion probability (P[BD]) were determined using EPI Suite
v.410 (http://www.epa.gov/oppt/sf/tools/methods.htm)[ 30,
31]. All inferential statistics and MRTD data analysis was
performed using MedCalc v.12 (MedCalc Software bvba,
Belgium). Artiﬁcial neural network analysis was performed
using Tiberius Data Mining Software v.6.1.9 (Tiberius Data
Mining Software Ltd. Pty, UK).
2.2. MRTD Training and Validation Datasets. The MRTD
of 31 structurally diverse antiretroviral drugs were taken
from the FDA MRTD database or package inserts. This
“clinical MRTD” dataset was randomly split into training
and validation subsets as shown in Table 1. Subsequently,
each of the calculated descriptors and clinical MRTD values
were correlated by multiple linear regression analysis and
the results used to identify statistically signiﬁcant property
descriptors. An error back propagation algorithm was used
Bias
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Figure 1: A neural network model was constructed with (2) hidden
neuron, (1) output variable that is Clinical MRTD, and (6) input
variablesthatis,OxidHL,P[BD],logBioHL,AlogP,ASol,MW.Total
number of patterns (23) were loaded in the data of which 23 were
complete and available for training. Two nonlinear neurons were
used and the model error minimization was stable for 20 minutes.
for network training, with learning rate set at 0.7. A tangent
sigmoid transfer function on the ﬁrst layer and two neurons
with a nonlinear transfer function on the hidden layer were
minimalisticstructuresusedtoreduceover-ﬁtting.Resultsof
MRTD versus molecular property descriptors with multiple
correlation coeﬃcients are listed in Table 2. For the neural
network model training, correlation and error statistics are
listed in Table 3.
2.3. Model Validation and Statistical Comparisons. The pre-
dictability of each of the multiple linear regression (MLR)
and neural network (TNN) models was evaluated by a cross-
validation procedure [32]. Each model was constructed on
the basis of the same training dataset and was subsequently
usedtopredicttheexcludedtestdata.Statisticalcomparisons
were performed between the clinical MRTD and predicted
MRTD values using the root mean squared error (RMSE),
Kendall’s correlation coeﬃcient (tau), P-value, and Bland
Altman plots for methods comparisons.
3. Results
3.1. Model Predicted versus Actual MRTD Estimates. In this
multivariable system, a quantitative relationship between
certain molecular property descriptors and maximum rec-
ommended therapeutic dose was characterized using two
datasets (i.e., MRTD and TEST). A multiple linear regression
(Table 2) and a 6-2-1-neural network model (Figure 1)f o r
the prediction ARVs maximum dose were constructed.
Table 1 lists summary statistics for the molecular property
descriptors and corresponding MRTD values in each dataset.
The ARVs in this study, although few in number, covered
a broad range (CV equal to 40% or greater) in terms of
the physicochemical (MW, ASol, AlogP) and bioaccumu-
lation properties (logBioHL, OxidHL, P[BD]) included. A
signiﬁcant diﬀerence in mean ASol between training set
(6.1489g/L) and TEST set (0.436g/L) was noted although
corresponding changes in lipophilic character were not as
great. Multiple linear regression analysis was performed with
results listed in Table 2. A statistically signiﬁcant but modest
correlation between two of the six descriptors, that is, P[BD]Computational and Mathematical Methods in Medicine 3
Table 1: Clinical MRTD data consisted of 23 training set compounds (italic) and 8 test set compounds (bold). Mean and standard deviation
statistics are shown indicating the distribution and central tendency of each molecular property descriptor.
Drug MRTD (mg/kg/day) OxidHL
(days) P[BD] (%) logBioHL
(days) AlogP (:) ASol (g/L) MW (Da)
Acyclovir 13.30 0.135 0.5475 −2.2874 −1.45 8.65 225.21
Ancitabine 20.00 0.139 0.2005 −2.418 −2.62 3.20 225.21
Delaviridine 6.67 0.034 0.0014 −2.3428 2.77 0.086 456.57
Didanosine 6.67 0.140 0.5085 −1.9956 −1.26 6.43 236.23
Famciclovir 25.00 0.051 0.991 −3.6235 0.13 1.32 321.38
Foscarnet 120.00 13.37 0.772 −2.4547 −1.63 16.76 126.01
Indinavir 16.70 0.038 0.0501 −4.6478 3.26 0.048 613.81
Lofexidine 0.040 0.123 0.0792 0.9861 3.31 0.15 259.14
Lamivudine 5.00 0.06 0.0719 −3.9261 −1.29 2.76 229.26
Rimantadine 3.33 0.171 0.4624 0.4539 3.28 0.009 179.31
Ribavirin 200.00 0.264 0.8963 −2.8715 −1.92 33.17 244.21
Valacyclovir 50.00 0.044 0.944 −3.3309 −1.03 1.49 326.41
Zalcitibine 0.0375 0.096 0.0909 −3.5083 −1.29 7.05 211.22
Zanamivir 0.333 0.038 0.8247 −4.4141 −2.29 1.49 332.32
Zidovudine 10.00 0.139 0.0432 −3.0445 −0.1 16.35 267.28
Saquinavir 33.330 0.052 0.9780 −3.9394 4.04 0.002 670.84
Darunavir 53.00 0.094 0.0001 −1.8175 1.76 0.067 547.66
Tipranavir 6.670 0.043 0.0000 −0.0265 5.71 0.0002 602.66
Ritonavir 20.00 0.105 0.9488 −4.61 4.24 0.0012 720.94
Maraviroc 20.00 0.129 0.0700 −0.2247 4.3 0.0106 513.66
Tenofovir 10.00 0.048 0.0016 −3.0098 −1.51 1.87 287.21
Nelﬁnavir 25.00 0.055 0.6868 −1.6709 6.00 0.0002 567.78
Stavudine 1.333 0.088 0.0768 −3.082 −0.8 40.51 224.21
n 23.00 23.00 23.00 23.00 23.00 23.00 23.00
mean 28.54 0.672 0.402 −2.5133 0.939 6.15 362.72
SD 45.53 2.769 0.394 1.5738 2.809 10.90 178.20
CV% 159.52 412.00 97.00 −62.620 299.04 177.25 48.86
Abacavir 10.00 0.040 0.0229 −2.1757 0.61 1.21 286.38
Emtricitabine 4.00 0.08 0.0566 −3.7784 −0.8 2.00 247.28
Raltegravir 30.07 0.094 0.0006 −2.6157 1.7 0.095 444.47
Nevirapine 3.000 0.167 0.0473 −3.7336 1.75 0.10 266.33
Efavirenz 10.10 0.254 0.0001 0.1111 3.88 0.008 315.67
Fosamprenavir 46.70 0.067 0.0007 −2.4135 0.84 0.068 585.68
Atazanavir 5.35 0.109 0.0202 −3.4392 4.37 0.003 704.96
Lopiravir 53.33 0.103 0.9933 −3.3281 4.07 0.002 614.86
n 8.00 8.00 8.00 8.00 8.00 8.00 8.00
mean 20.32 0.114 0.143 −2.672 2.05 0.436 433.20
SD 20.29 0.067 0.344 1.278 1.878 0.753 180.48
CV% 99.86 58.99 241.300 −47.830 91.50 173.000 41.66
(Rz = 0.427, P = 0.035), ASol (Rz = 0.476, P = 0.014)
and actual MRTD value is noted. MRTD values appear
to increase with P[BD], ASol, and OxidHL; but decrease
with increasing logBioHL, AlogP, or MW. The multiple
correlation coeﬃcient (MCC = 0.7727), residual error (RSD
= 33.89), and ANOVA (P = 0.013) indicate acceptable
predictability of the multiple regression model for ARVs
maximum dose. A multiple linear regression equation used
for the prediction of MRTD is as follows:
−34.3303 − 12.20 ∗

AlogP

+2 .1249 ∗ (ASol)
+15.90 ∗

logBioHL

+0 .2159 ∗(MW)
+5.659 ∗(OxidHL)+4 6 .5133 ∗(P[BD]).
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Table 2: The results of the multiple linear regression analysis for antiretroviral drugs versus MRTD. In the training, dataset only two of
the six molecular descriptors showed a statistically signiﬁcant correlation with therapeutic dose, that is, P[BD] (P = 0.0349) and ASol (P =
0.0140). A multiple regression model equation coeﬃcients are listed with there standard errors, coeﬃcient of determination (R2 = 0.5970),
multiple correlation coeﬃcient (MCC = 0.7727) and residual standard deviation (RSD = 33.89).
Multiple linear regression n = 23 R2 = 0.5970 RSD = 33.89 MCC = 0.7727
independent variables Coeﬃcient SE P-value Rz
Constant −34.3303
AlogP −12.1995 6.6976 0.0873 −0.221
ASol 2.1239 0.7697 0.0140 0.476
logBioHL 15.9000 8.0377 0.0654 −0.071
MW 0.2159 0.1015 0.0494 −0.116
OxidHL 5.6589 2.8478 0.0643 0.448
P[BD] 46.5133 20.1746 0.0349 0.427
ANOVA F-ratio = 3.9507 P = 0.013
Table 3: The results of the neural network analysis for antiretroviral drugs versus MRTDs. All molecular descriptors show weak correlation
with MRTD except for ASol, OxidHL, and P[BD]. The 6-2-1 neural network model predicted training set MRTD values with high accuracy
(R2 = 0.992, MAX = 13.64, P<0.001). No multicollinearity between independent variables was observed in the training set.
6-2-1 neural network n = 23 R2 = 0.992 MAX = 13.64 RMSE = 5.53
Model versus clinical MRTD P<0.001 Learning rate = 0.700
Independent variables Correlation coeﬃcients R2
AlogP −0.221 0.049
ASol 0.476 0.226
logBioHL −0.071 0.005
MW −0.116 0.013
OxidHL 0.448 0.201
P[BD] 0.427 0.182
ANOVA F-ratio = 1340.73 P<0.001
Theresultsoftheneuralnetworkmodelforantiretroviral
MRTDs is shown in Table 3. All molecular descriptors show
weak correlation with MRTD except ASol, OxidHL, and
P[BD]. The 6-2-1 neural network predicted training set
MRTD values with high accuracy (R2 = 0.992, MAX =
13.64,P<0.001).Nomulticollinearitybetweenindependent
variables was observed in the training set. SPSS code for the
6 - 2 - 1n e u r a ln e t w o r km a yb ee x e c u t e da sf o l l o w s :
COMPUTE Var1 = ((OxidHL ∗
(−0.543086558961242)) +
3.63976611815824)
+ ((Pr BD ∗ (−5.67413921537257)) +
2.81153598121711)
+ ((LogBioHL ∗ (0.40828801067156)) +
0.747514104338025)
+ ((ALogP ∗ (−0.848110602763694)) +
1.43330691867064)
+ ((Sol ∗ (−2.55399028293542E−02)) +
0.517313285798853)
+ ((MW ∗ (1.40343495376914E−02)) −
5.94322423917294)
+ 3.86733992096867.
COMPUTE Var2 = ((OxidHL ∗
(8.23491975851945E−02)) -
0.551904322215974)
+ ((Pr BD ∗ (3.12529587401663)) -
1.54858410557524)
+ ((LogBioHL ∗ (0.431493610228662)) +
0.790000076287146)
+ ((ALogP ∗ (−0.04107624611641)) +
6.94188559367329E−02)
+ ((Sol ∗ (4.12997852313067E−02)) −
0.836531279838639)
+ ((MW ∗ (1.05078568602304E−03)) −
0.444983569959981)
+ 9.28741349960935E-02.
COMPUTE Var3 = −0.535249116383622.
Execute.
COMPUTE Var1 = 0.108990429907616 ∗ Var1.
COMPUTE Var2 = 1.44376333322051 ∗
(Exp(Var2) − Exp(-Var2)) / (Exp(Var2) +
Exp(−Var2)).
COMPUTE Var3 = Var3.Computational and Mathematical Methods in Medicine 5
Table 4: Test dataset Goodness of ﬁt comparisons. Clinical MRTD values from 8 ARVs were using as and external test dataset the validate
modelpredictability.Modelperformanceischaracterizedhereintermsofrootmeanssquarederror(RMSE),Kendall’scorrelationcoeﬃcient
(tau), and Type II error probability (P-value).
Drug MRTD MLR SE TNN SE
Abacavir 10.00 −10.6738 427.4060 6.4861 12.3474
Emtricitabine 4.00 −23.9239 779.7441 3.3678 0.3996
Raltegravir 30.07 0.0628 900.4320 19.7700 106.0900
Nevirapine 3.00 −54.1862 3270.2614 −16.5700 382.9849
Efavirenz 10.10 −10.2863 415.6012 −5.7782 252.1172
Fosamprenavir 46.70 44.0515 7.0145 50.7500 16.4025
Atazanavir 5.35 11.4360 37.0393 29.8700 601.2304
Lopiravir 53.33 42.6361 114.3594 64.5900 126.7876
Mean 20.32 −0.1105 RMSE = 27.27 19.06 RMSE = 13.67
Kendall’s tau 0.714 0.643
P-value 0.019 0.035
Execute.
COMPUTE Tiberius MRTD = ((((Var1 +
Var2 + Var3)/2.0) + 0.5) ∗ 199.9625)
+ 0.0375.
Execute.
3.2. Model Validation and Statistical Comparisons. Each of
the models was then validated using external TEST MRTD
dataset and a cross-validation procedure. Model “goodness
ofﬁt”andpredictabilityaresummarizedin Table 4.RMSEof
the 6-2-1 neural network (RMSE = 13.67) was substantially
less the multiple linear regression model (RMSE = 27.27).
Comparison of model predictivity was conﬁrmed with TNN
having maximum squared error (SE = 601.23) compared to
MLR (SE = 3270.26). Model Figure 3 correlation with the
clinical MRTD values using Kendall’s correlation coeﬃcient
was, however, greater for the MLR (tau = 0.714, P = 0.019)
than the resultant 6-2-1 neural network model (tau = 0.643,
P = 0.035). Bland Altman plots for methods comparison
further illustrate the predictive value of the neural network
(TNN) and multiple linear regression (MLR) models. The
upper and lower limits of agreement for the MLR (58.3,
−17.4) and TNN (29.8, −27.3) are illustrated in Figure 2.
While it can be seen that all of the diﬀerences lie between
these limits, MLR model limits of agreement were wider
than the TNN model, which were more narrow and nearly
symmetrical.
4. Discussion
MRTD values and SMILES codes for antiretroviral drugs
were collected from the FDA MRTD database which
is a highly reliable source pharmacologic activity based
on extensive clinical evidence (http://www.fda.gov/cder/).
The ALOGPS+ program was used for the calculation of
molecular mass (MW), solubility (ASol), and lipophilicity
(AlogP) without alteration. The precision and robustness of
these tools are well established in the pharmaceutical and
modeling community and its predictive power concerning
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Figure 2: Method comparisons graph. MRTD values predicted by
multiple linear regression (hollow squares, ) nearly traced those
values predicted by the 6-2-1 neural network (solid squares, )a s
shown. Multiple linear regression estimates for MRTD were consis-
tently lower that those predicted by the neural network model.
the input parameters in question are published on the
company website (http://www.vcclab.com/) and cited in the
manuscript [28, 29, 33]. Independent validation of the
parameters calculated with ALOGPS has been published
[33, 34] and the estimates were found to be appropriately
accurate for the use intended. The bioaccumulation input
parameters, oxidation half life (oxidHL), log biotransfor-
mation half life (logBioHL), and biodegradation probability
(P[BD]) were calculated using the EPI Suite software which
is publically available and has been validated in hundreds
of modeling experiments for the estimated parameters. EPI
Suite software is continuously updated and the predictive
power of its latest version is always available at the website
(http://www.epa.gov/oppt/sf/tools/methods.htm). None of6 Computational and Mathematical Methods in Medicine
−60
−40
−20
0
20
40
60
80
100
−40 −2 00 2 04 06 0
Average of clinical MRTD and predicted MRTD
+1.96 SD
58.3
Mean
20.4
−1.96 SD
−17.4
C
l
i
n
i
c
a
l
 
M
R
T
D
—
p
r
e
d
i
c
t
e
d
 
M
R
T
D
(a)
−60
−40
−20
0
20
40
60
−20 0 20 40 60
Average of clinical MRTD and predicted MRTD
29.8
1.3
−27.3
+1.96 SD
Mean
−1.96 SD
80
C
l
i
n
i
c
a
l
 
M
R
T
D
—
p
r
e
d
i
c
t
e
d
 
M
R
T
D
(b)
Figure 3: Bland Altman plot for method comparisons. Bland Altman plots are shown for (a) multiple linear regression predicted versus
clinical MRTD, and (b) neural network model predicted versus clinical MRTD. Horizontal lines are drawn at the mean diﬀerence, and at the
limits of agreement. All predicted values were within limits of agreement for both models, althought these limits were more narrow for the
neural network model estimates. The plots are useful revealing the relationship between the diﬀerences and the averages, the slight deviation
from symmetry in the multiple regression indicates some systematic bias but no possible outliers were identiﬁed.
the parameters were log-transformations of the software
outputbutinsteadusedasdirectinputvaluesforthetraining
set. Although some of the predictor values ranged over 3
orders of magnitude, this did not appear to adversely aﬀect
comparisons of the MLR or ANN methods. Furthermore,
because of the highly diverse nature of antiretroviral com-
pounds in terms of physicochemical descriptors and split-
data validation procedure with randomly selected training
and test sets instead of cross-validating scheme. It is our
intention to adapt the method as new ARV drugs become
listed in evolving FDA database.
We began our study looking at dose-related adverse ef-
fects of commercial antiretroviral drugs or new ARVs in
development. Although the appearance of serious long-
term metabolic complications, such as cardiovascular distur-
bances[35],hyperlipidemia[35,36],anddiabetes,havebeen
extensively reported [35, 37], few reports on computational
models to predict these dose-limiting toxicities [38, 39]
can be found in the literature. A mathematical model to
predict the optimal dosing regimen for AIDS therapy has
been reported [40], but in this case, CD4+ cell counts and
knowledge of the adherence interval of individual patients is
required to adjust the dose. While the model was eﬀective at
reducing dose-limiting toxicities in an AIDS patient popu-
lation, it cannot be applied to nonapproved ARV formula-
tions or to drugs in development. Since the overwhelming
majority of anti-HIV drugs demonstrate eﬃcacy over a small
rangeoftreatmentdoses,MRTDpredictingmodelswouldbe
beneﬁcial to the drug delivery scientist who needs to design
experiments based on the most eﬀective therapeutic dose
of the medication [41]. The MRTD is empirically derived
from human clinical trials, thus it is a direct measure of
the threshold for dose-related adverse eﬀects in humans.
Prediction of the MRTD from molecular structure is of
importance for both new and existing drugs which may
require modiﬁcations to improve their aqueous solubility
or bioavailability in vivo. ARVs ﬁt this description also
and are excellent subject molecules for predictive modeling
to estimate maximum dose. Unfortunately, the number of
antiretroviral drugs with established MRTD is yet small,
so the development of models speciﬁcally of ARVs is both
tedious and rare.
The molecular descriptors used in this study were select-
ed to represent physicochemical (MW, AlogP, ASol) and
bioaccumulation (OxidHL, P[BD], logBioHL) property
inﬂuencestherapeuticdose.Althoughmolecularweightdoes
not strongly correlate with toxicity of most compounds, the
larger the molecular size of a compound, the smaller its
membrane permeability and diﬀusion coeﬃcient become
[34]. Therefore, compounds with higher weights are less
likely to be absorbed, which limits their systemic toxicity.
Results of this study predict no correlation between molecu-
lar weight and maximum ARV dose. In contrast, bioactivity
and drug toxicity almost always increase with increasing
lipophilicity. This is due in part to the fact that lipophilic
molecules tend to cross cellular membranes more readily
increasing exposure and residence in the body. In addition,
lipophilic drugs are characterized by increased plasma pro-
tein binding, thus an assessment of lipophilicity is almost
always included in the physicochemical evaluation of a
drug because of its close association with pharmacologic,
permeability and potential bioaccumulation [42, 43]. OurComputational and Mathematical Methods in Medicine 7
results here did not indicate AlogP or lipophilic character as
having any inﬂuence on ARV dose. The aqueous solubility
of a compound signiﬁcantly aﬀects its absorption and
distribution characteristics. Typically, low solubility goes
along with a poor absorption and, therefore, its systemic
toxicity reduced, however, local irritability may develop
and/or reduced elimination rates, both are characteristic of
drugs with low aqueous solubility. For highly potent drugs,
increasing solubility usually enhances the elimination rate
and lowers systemic half life, [44]. This means that for
ARVs with low aqueous solubility, some correlation with
maximum therapeutic dose (as we has shown) is likely to be
observed.
Any chemical (even water) can produce toxic side eﬀects
in the body if allowed to accumulate to suﬃciently large
concentrations.Whilemuchoftheeﬀortinbioaccumulation
modeling [43, 45] has been initiated by scientists estimating
the equilibrium distribution of chemicals between organ-
isms and their environments (e.g., ﬁsh-water, plants-soil),
eﬀective physicochemical property estimation routines (i.e.,
PERs)haveresultedfromthesestudiesthatmaybeappliedto
similarbiodistribution problemsinpharmaceuticalresearch.
For example, oxidation half life (OxidHL) is an estimate
of the molecules ability to form stable hydroxyl radicals
or to interact with such moiety under ambient conditions.
Formationofhydroxyl-radicalsisoftenassociatedwithdose-
limitingtoxicities.Althoughinourstudies,oxidationhalflife
was not statistically signiﬁcant in the prediction of MRTD.
Another bioaccumulation descriptor, biotransformation half
life (logBioHL), is the (linearized) fraction of drug mass
in the whole body that has been metabolized per day.
Our estimates do not account for the formation of speciﬁc
metabolites which may be toxic nor do they identify speciﬁc
pathwaysin the process (i.e., phase I redox reactions or phase
II type conjugation reactions). Consequently, logBioHL was
not correlated with MRTD in the present study and was a
weaker bioaccumulation property descriptor in comparison
to oxidation half life or biodegradation probability P[BD].
The probability of biodegradation attempts to combine
both oxidative and biotransformation susceptibility of the
structure to give an estimate of overall persistence. P[BD]
estimates are based upon molecular fragments [46–48]
and in our investigation showed only moderate correlation
with MRTD in both multiple linear regression and neural
network models. Each of the models was evaluated for
predictiveaccuracyandbystatisticalcomparison.Intermsof
predictability, root mean squared errors were larger for the
multiple linear regression than the neural network model.
Some advantages of ANN over MLR models were illustrated
in the current study.
Artiﬁcialneuralnetworks(ANNs)arebiologicallyinspir-
ed data-mining algorithms which work by detecting the
patterns and relationships in data. We used the back prop-
agation rule in which the neural network is trained to map
a set of input data by iterative adjustment of the weights. A
tangent sigmoid transfer function on the ﬁrst layer and two
neurons with a nonlinear transfer function on the hidden
layer were minimalistic structures used to reduce overﬁtting.
Our training processes for TNN were allowed to run until no
changeinRMSEwasobservedfor20minutes,atwhichpoint
the model was saved. This learning method is commonly
used for neural network predictive models given dose-
response type data. However, ANNs have several limitations,
a major theoretical concern is the “black box” nature of the
output, that is, conclusions are generated without mecha-
nistic explanations. ANNs also are limited by the quality
of their data and may need to be retrained periodically if
its performance changes over time. This is not necessarily
counterproductive, since it indicates robustness in the model
which adapts to changes in the predictive criteria. Real-time
monitoring of the training process is also important since
overtrainingcaneasilyoccur,especiallywhenthedatasetsare
small in size. This is may be one of the unique advantages of
real-time visualization of the data-mining process allowing
theinvestigatortomake“intermediate evaluations”ofmodel
predictability and then continue training until the reliability
and accuracy required of the predictions are met.
In conclusion, antiretroviral drugs are a chemically di-
verse class of compounds in terms of both physicochemical
properties and bioaccumulation potential. However, com-
mercial ARVs may be categorized for predictive modeling
purposes into two groups based on aqueous solubility and
lipophilic character, in which hydrophilic compounds may
be administered at higher doses (MRTD) and prediction
of their MRTD value may be possible using simple mul-
tiple linear regression models. In contrast, the prediction
of MRTD values for antiretrovirals with poorer aqueous
solubility would be the most eﬀective when the neural
network approach is used and when both physicochemical
and bioaccumulation property descriptors are available for
training. With regard to future studies, ANN represents a
promising tool for predicting maximum therapeutic dose,
especially for antiretroviral drugs with narrow therapeutic
index in the treatment of AIDS.
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